Testimony Before the FDA’s Arthritis Advisory Committee and Drug Safety and Risk Management Advisory Committee Regarding Febuxostat

View complete testimony as PDF

View PowerPoint slides as PDF

View Press Release

In testimony before a joint meeting of the Food and Drug Administration’s Arthritis Advisory Committee and Drug Safety and Risk Management Advisory Committee, Public Citizen urged the committees to recommend that the FDA immediately remove from the market the widely used gout medication febuxostat because it poses unique, serious risks – include the risk of dying from cardiovascular disease – but offers no unique benefit. Public Citizen had requested such action in a citizen petition submitted to the agency on June 21, 2018.

See Public Citizen’s other work on febuxostat.